ArticleScientific reports2025
Improvement of osteogenic differentiation in umbilical cord-derived human mesenchymal stem cells through specific MiRNA inhibition.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Study on the Expression of MiR-642b-3p in Spontaneous Intracerebral Hemorrhage and Its Regulatory Mechanism on Endothelial Cell Injury.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Umbilical cord-derived human mesenchymal stem cells (UC-hMSCs) are multipotent stem cells with great potential for treating bone diseases. Although they can be easily isolated from umbilical cord tissue, their osteogenic differentiation is less efficient than differentiation of bone marrow-derived hMSCs (BM-hMSCs). Improving osteogenic differentiation of UC-hMSCs is essential for their clinical use. This study identified specific microRNAs (miRNAs) that inhibit osteogenic differentiation and explored their regulatory mechanisms to improve the osteogenic potential of UC-hMSCs. High-throughput miRNA expression analysis was performed to identify miRNAs involved in osteogenic differentiation. Quantitative real-time RT-PCR confirmed the expression levels of these miRNAs during osteogenic differentiation. The effects of specific anti-miRNAs on osteogenic differentiation were evaluated using alkaline phosphatase (ALP) activity, Alizarin Red S staining, and osteogenic gene expression assays. Analysis revealed significant differential expression of 806 miRNAs in high-osteogenic UC-hMSCs and 760 miRNAs in low-osteogenic UC-hMSCs. Four miRNAs-miR-21, miR-27b, miR-29a, and let-7b-were significantly down-regulated during osteogenic differentiation in high-osteogenic UC-hMSCs but remained elevated in low-osteogenic UC-hMSCs. Inhibition of these miRNAs using specific anti-miRs significantly increased osteogenic gene expression, ALP activity, and matrix mineralization. These effects could be partially mediated by modulation of the PI3K/Akt and Wnt/β-catenin signaling pathways, which led to the up-regulation of RUNX2 expression in UC-hMSCs. Our findings indicate that miR-21, miR-27b, miR-29a, and let-7b are important regulators of osteogenic differentiation in UC-hMSCs. Targeting these miRNAs could enhance osteogenic differentiation by modulating the PI3K/Akt and Wnt/β-catenin signaling pathways, leading to increased RUNX2 expression. These findings provide valuable insights into the role of specific miRNAs in regulating osteogenic differentiation of UC-hMSCs and highlight potential therapeutic strategies for bone regeneration through miRNA modulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.